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Metabolic syndrome: A predictor of adverse
outcomes after carotid revascularization
Clinton D. Protack, MD, Andrew M. Bakken, MD, Jiaqiong Xu, PhD, Wael A. Saad, MD,
Alan B. Lumsden, MD, and Mark G. Davies, MD, PhD, MBA, Rochester, NY; and Houston, Tex
Background: Metabolic syndrome (MetS) is rapidly increasing in prevalence and is associated with carotid plaque
development and is a risk factor for stroke. The aim of this study is to describe the outcomes for patients with MetS after
carotid revascularization (carotid endarterectomy [CEA] and carotid stenting [CAS]).
Methods: A database of patients undergoing carotid revascularization for primary atherosclerotic lesions was queried from
1996 to 2006. MetS was defined as the presence of >3 of the following criteria: blood pressure >130 mmHg/>90 mm
Hg; Triglycerides >150 mg/dL; high-density lipoproteins (HDL) <50 mg/dL for women and <40 mg/dL for men;
fasting blood glucose >110 mg/dL; or Body Mass Index (BMI) >30 kg/m2. Multivariate and Kaplan-Meier analyses
were performed to outcomes. The average follow-up period was 4.5 years. A major adverse event (MAE) was defined as
the occurrence of stroke, myocardial infarction (MI), or death.
Results: A total of 921 patients (mean age: 71 10 years; 64%male) underwent 750 CEAs and 171 CAS. Thirty-one percent
were identified as havingMetS, 48%were asymptomatic, 87%had hypertension, 27%had hyperlipidemia, 32%were considered
diabetic, and 14% had chronic renal insufficiency. The morbidity and mortality rates for all patients were 16.9% and 1.1%,
respectively. The 30-day combined stroke/death rate was 3.6%. The 30-day MAE rates were: 6.7% vs 3.3% for MetS vs
No-MetS (P .02). The 90-dayMAE rates were 8.7% vs 4.9% forMetS vsNo-MetS (P .03).MetS patients weremore likely
to experience a complication thanNo-MetS patients (23% vs 14%,P .001). ByKaplan-Meier analysis, therewas no difference
between MetS and No-MetS patients with respect to patency, restenosis, re-intervention, or survival, but a difference existed
for freedom from stroke, MI, and MAE. The difference between stroke rates was maintained between MetS and No-MetS,
when subgrouped by thosewith andwithout symptoms. For patients with diabetesmellitus (DM), thosewithMetS had a 68%
and 410% higher risk of developing an MAE and MI, respectively. However, for patients without diabetes, MetS was not
significantly associated withMAE, stroke, orMI. No factors were found to be significantly associated with risk of stroke in all
cases (in all patients, patients with diabetes, and patients without diabetes).
Conclusion:MetS is prevalent among patients undergoing carotid revascularization. MetS patients are at a greater risk for
perioperative morbidity as well as stroke, MI, and MAE during follow-up when compared to patients without MetS.
Long-term stroke prevention is poor in the presence of MetS. MetS should be considered a significant risk factor for
patients undergoing carotid revascularization. (J Vasc Surg 2009;49:1172-80.)Metabolic Syndrome (MetS) is a condition manifested
by hypertension, obesity, and a prediabetic state (high
fasting blood glucose, high triglycerides, and low high-
density lipoproteins [HDL]) and is rapidly increasing in
prevalence1 and is an emerging risk factor for cardiovascular
morbidity andmortality.2 Prior studies have shown that the
presence of MetS can be correlated with increased carotid
intima-media thickness in both men3 and women.4 MetS
has also been demonstrated to amplify vascular wall thick-
ness and stiffness5 and create an overall prothrombotic
state.6 Carotid atherosclerosis is increased in incidence and
progression in patients with MetS.7 Patients with MetS
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1172exhibit impaired fibrinolysis through increased plasmino-
gen activator-1 levels compared to those without MetS.8
The effects of MetS and stroke are not limited to preclinical
pathophysiologic observations. The risk of stroke and tran-
sient ischemic attack (TIA) are increased for patients in the
presence of MetS.9 McGirt et al10 have already demon-
strated that an elevated operative day glucose levels in-
creases the risk of perioperative stroke, myocardial infarc-
tion (MI), and death after carotid endarterectomy (CEA).
The risk of developing atrial fibrillation (another potential
cause of stroke) postoperatively from coronary artery by-
pass grafting is increased for patients with MetS.11
Despite these observations of MetS’s influence on vas-
cular remodeling and its poor prognostic factor during
cardiovascular procedures, the outcomes after carotid re-
vascularization have not been studied. The primary objec-
tive of this report is to analyze the impact of the presence of
MetS on short-term (30-day) and long-term outcomes of
patients undergoing carotid revascularization.
METHODS
Study design. A database of patients undergoing ca-
rotid revascularization from 1996 to 2006 was queried.
Patients undergoing CEA and carotid artery stenting
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ease were analyzed. Vessels treated for intimal hyperplasia,
in-stent restenosis, radiation-induced arteritis, and trauma
were excluded. Data utilization fell under the category of
secondary use of pre-existing data.
Procedures. Patients underwent carotid endarterec-
tomy or carotid stenting where carotid stenosis was 80%
for asymptomatic and 50% for symptomatic patients was
detected on duplex scan imaging and was confirmed in
most cases on computed tomography angiography or mag-
netic resonance angiography. Routine pre- and postproce-
dural neurology consultations were not requested, unless
the patient was symptomatic. For carotid endarterectomy,
patients were maintained on aspirin therapy and the major-
ity underwent endarterectomy under regional block with
the remainder undergoing general anesthesia with electro-
encephalography (EEG) monitoring. Both Dacron patch
angioplasty and eversion endarterectomy were performed.
For carotid stenting the patient was given clopidogrel (75
mg/dL) and aspirin (81 mg) beginning 3 days before the
intervention. After the stenting procedure, clopidogrel was
continued for 1 month, and aspirin was continued for life.
All patients undergoing carotid stenting received an intra-
venous heparin bolus (100 U/kg) to achieve systemic
anticoagulation during the carotid intervention (activated
coagulation time [ACT] 250 seconds). All carotid stent-
ing procedures were performed in fixed imaging procedure
rooms under conscious sedation. The technique of stenting
with an embolic protection device has been described pre-
viously.12 Self-expanding monorail carotid stent (Wall-
stent, Boston Scientific, Natick, Mass; Precise, Cordis,
Warren, NJ; or Acculink, Guidant, Santa Clara, Calif) were
deployed across the internal carotid stenosis. Post stenting
balloon angioplasty was performed with either a 5- or
6-mm-diameter angioplasty balloon, depending on the ap-
pearance of the completion angiogram. Procedures were
performed with local Institutional Review Board (IRB)
approval and/or as part of an approved multi center clinical
trial and followed Center for Medicare services (CMS)
guidelines. Patients, after both CEA and CAS, were rou-
tinely kept in the hospital overnight and discharged home
on the following day. In general, patients were followed by
duplex ultrasound scan every 6 months for 2-3 years and
then yearly thereafter if there was no contralateral disease. If
there was50% disease present, 6 monthly follow-ups was
the norm. Lesions 80% were intervened on during fol-
low-up. All duplex ultrasound scans were performed at
approved vascular laboratories accredited by the Intersoci-
ety Commission on Accreditation of Vascular Laboratories
using the University of Washington criteria.
Definitions. MetS was defined based on the presence
of three or more of the following five criteria: hypertension
(systolic blood pressure140 mmHg or diastolic pressure
90mmHg on three occasions during a 6-month period),
reduced high-density lipoprotein cholesterol (40 mg/dL
for men, 50 mg/dL for women), elevated triglycerides
(150 mg/dL), impaired glucose control (110 mg/dL
fasting serum glucose), and a body mass index (BMI)30.0 kg/m2.13,14 Coronary artery disease was defined as
a history of angina pectoris, MI, congestive heart disease, or
prior coronary artery revascularizations. Cerebrovascular
disease included a history of stroke, transient ischemic
attack, or carotid artery revascularization. Hypercholester-
olemia was defined as fasting cholesterol (200 mg/dL).
Diabetes was defined as a fasting plasma glucose (110
mg/dL) or an HbA1c 7%. Diabetics were characterized
as insulin dependent diabetes mellitus (IDDM) or non-
insulin dependent diabetes mellitus (NIDDM). Hyperten-
sion was defined as a systolic blood pressure greater than
140mmHg or diastolic blood pressure greater than 90mm
Hg on three occasions during a 6-month period. Resteno-
sis was defined as the development of 50% stenosis.
Technical failure was defined as an inability to perform the
intended procedure or if a re-intervention occurred within
30 days of the initial procedure. A major adverse event
(MAE) was defined as an ipsilateral stroke, MI, or death
during follow-up. The time to MAE was determined as the
first occurrence of any of the three MAE factors (stroke,
MI, or death). Unlike Stenting with Angioplasty and Pro-
tection in Patients at High Risk for Endarterectomy
(SAPPHIRE),15 patients did not have a troponin series
performed or formal neurological consultations postproce-
dure. A death 30 days of the procedure was considered
procedure-related. Perioperative was defined as a stroke
occurring during the hospital admission and less than 30
days postprocedure. A major complication was defined as
any event, regardless of how minimal, not routinely ob-
served after therapy that required treatment with a thera-
peutic intervention or rehospitalization 30 days of the
procedure.
Statistical analysis. Measured values are reported as
percentages or means  standard deviations (SDs). Rates
for comorbidities, complications, and 30-day outcomes
were compared between patients with MetS and No-MetS
by 2 test. Survival, patency, neurologic-free, and MAE
rates were calculated using Kaplan-Meier analysis and are
reported using current Society for Vascular Surgery (SVS)
criteria.16 Standard errors are reported in Kaplan-Meier
analyses. The log-rank test was used to determine survival
differences between patients with MetS and No-MetS. The
Cox proportional hazards models were used to examine the
associations between MetS and MAE, stroke, and MI,
adjusted for age, gender, history of MI, congestive heart
failure (CHF), atrial fibrillation (AFIB), and chronic ob-
structive pulmonary disease (COPD). Interactions between
MetS and all covariates were not statistically significant.
The proportionality assumption of Cox models was as-
sessed by including time-dependent interaction of each
covariate with survival time in the model. There was no
evidence of violation of this assumption for any covariate.
Statistical significance is defined as two-tailed P value of less
than .05 for all tests.
RESULTS
Patient population. A total of 921 carotid revascular-
izations were performed in 843 patients. The mean age was
d enda
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were greater than 80 years of age. Of them, 64% were male.
Forty-eight percent of the patients were asymptomatic. The
most common presenting symptom was ipsilateral TIA in
30% of the patients, 19% presented with ipsilateral stroke,
and 2% presented with vertebrobasilar symptoms that were
believed to be a watershed phenomenon. All of the patients
with vertebrobasilar symptoms had 80% stenosis at pre-
sentation.
Metabolic syndrome status. Two hundred eighty-
eight patients (31%) were identified as having MetS. MetS
and No-MetS patients had equivalent rates of patients
presenting symptomatically. Of the five criteria used to
define MetS, hypertension was most prevalent among the
patients with an overall rate of 87%. Forty-one percent had
elevated fasting blood sugar. Thirty percent had elevated
triglycerides (150mg/dL), 27% had reducedHDL (50
mg/dL for females and 40 mg/dL for men), and 26%
had an elevated BMI (30 kg/m2). The distribution of
MetS scores were: 5 (1%), 4 (9%), 3 (21%), 2 (31%), 1
(31%), and 0 (7%).
Comorbidities. Twenty-seven percent of the pa-
tients had a previous MI, and 12% had a history of
congestive heart failure (Table I). Eighty-seven percent
had hypertension. Two hundred ninety-three patients
were diabetic: 33 (4%) with IDDM and 260 (28%) with
NIDDM. One hundred four (11%) were hypothyroid.
MetS patients were more likely to have a prior MI (40%
vs 21%, P .001), hypertension (98% vs 82%, P .001),
NIDDM (50% vs 19%, P  .001), IDDM (7% vs 2%, P 
.001), and a serum creatinine greater than 1.5 mg/dL
(19%, vs 12%, P  .004). MetS patients were more likely
to have current or prior tobacco use (84.5% vs 61.9%,
P  .001) (Table I). The two procedural groups had
several significantly different rates of comorbidities. The
CAS group had a greater proportion of patients with a
history of MI, CHF, serum creatinine 1.5 mg/dL,
MetS, and were older (Table I).
Procedures. Of the 921 carotid revascularizations,
750 (81%) were by CEA and 171 (19%) were by CAS. Of
the 921 CEAs performed, 49% were performed under
cervical block while 51% under general endotracheal anes-
Table I. Patient comorbidities
Total MetS
n  921 n  288
n (%) n (%)
Myocardial infarction 27% 40%
Congestive heart failure 12% 14%
Hypertension 87% 98%
Non-insulin-dependent DM 28% 50%
Insulin-dependent DM 4% 7%
Hypothyroid 11% 12%
Cr 1.5 mg/dL 14% 19%
MetS, Metabolic syndrome; No-MetS, no metabolic syndrome; CEA, caroti
*Significant.thesia. Of the CEAs performed, the arteriotomy closurewas performed by eversion in 64% of cases and patch
(prosthetic or vein) in 36%. During CAS, 137 patients
(80%) involved successful deployment of an embolic pro-
tection device (EPD), 10 (6%) failed attempts of EPD
deployment occurred, and 24 (14%) did not attempt EPD
usage. Technical success was achieved in 98.9% of proce-
dures initiated. For all patients, the 30-day and 90-day
mortality rates were 1.1% and 2.1%, respectively. Perioper-
ative was defined as a stroke occurring during the hospital
admission and less than 30 days (22 events, 2.4%). The
30-day stroke rate was 28 events, 3.0%. Thus, 6 patients
were discharged post-procedure and returned within 30
days with a cardiovascular accident (CVA).
The overall morbidity rate was 16.9%. MetS patients
experienced a 22.9% rate and No-MetS patients experi-
enced a 14.3% rate (P .001). Complications were divided
into systemic, regional, and local groups. The systemic
complications were 16 (1.7%) cardiac, 9 (1.0%) pulmonary,
and 2 (0.2%) renal. Among regional complications, brady-
cardia (2.9%) and hypotension (2.5%) were most common
(see Table II for a complete list). The most common local
complications were hematoma (7.1%) and vasospasm
(1.1%), (see Table II for a complete list). Among individual
complications, MetS patients suffered greater rates of ipsi-
lateral stroke (4.6% vs 1.4%, P  .004), bradycardia (4.6%
vs 2.2%, P .048), hypotension (4.2% vs 1.7%, P .025),
and vasospasm (2.5% vs 0.5%, P .007) when compared to
No-MetS patients. There was no complication category
that was higher in No-MetS patients when compared to
MetS patients. BMI was not uniquely associated with 30-
day mortality or morbidity.
Outcomes. The 30-day all-cause mortality rate was
1.1% (10 deaths). The combined stroke and death rate for
all patients was 3.6% (33 events). During the first 30 days,
28 (3.0%) experienced an ipsilateral stroke, 12 (1.3%) had
an MI, and 10 (1.1%) required re-intervention. The overall
30-day and 90-day ALL stroke rate was 3.8% and 4.1%, for
all patients. The overall 30-day and 90-day MAE rates were
4.3% and 5.9%, respectively, for all patients. MetS patients
had higher 30-day and 90-day MAE rates (6.7% vs 3.3%,
P  .020 and 8.8% vs 4.6%, P  .011, respectively).
Long-term follow-up revealed 15 (2%) vessel occlu-
et-S
P value
CEA CAS
P value
633 n  750 n  171
) n (%) n (%)
%  .001 23% 46%  .001*
% .102 7% 30%  .001*
%  .001 87% 88% .661
% .001 3% 5% .19
%  .001 29% 27% .668
% .603 11% 14% .209
% .004 12% 23%  .001*
rterectomy; CAS, carotid artery stenting; DM, diabetes mellitus.No M
n 
n (%
21
10
82
19
2
11
12sions and 132 (14%) restenosed vessels. No statistical dif-
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dom from restenosis. The median time to vessel restenosis
was 18.2 months. By Kaplan-Meier analysis the 5-year
patency and freedom from restenosis was 98.0  0.6% and
78.0  1.9%, respectively. Between the two groups there
was no difference in patency and restenosis rates (Table III,
online only).
Themean duration of follow-up was 4.5 years (range of
0.0 to 11.8 years). During follow-up, 33 (4%) required
re-intervention, 50 (5%) experienced an ipsilateral stroke,
89 (10%) had an MI, and 259 (28%) expired. The cumula-
tive MAE rate was 35% (321 patients) during follow-up
(Fig 1).
MetS patients experienced greater stroke, MI, and
MAE rates when compared to No-MetS by Kaplan-Meier
analysis. Survival did not differ between groups. MetS
patients had a 1-, 2-, and 3-year freedom from ipsilateral
stroke rates of 95  1%, 95  1%, and 93  1%, while
No-MetS patients had rates of 97 1%, 97 1%, and 96
1% (P .027) (Fig 2). This difference was maintained if the
patients were subgrouped as symptomatic or asymptom-
atic. The 1-, 2-, and 3-year freedom fromMI rates between
MetS and No-MetS were 95 1%, 92 2%, 88 2%, and
98  1%, 96  1%, and 96  1%, respectively, (P  .001)
(Fig 3). Total survival rates were 94  1%, 90  1%, 86 
1% (Fig 4). MetS patients had an MAE rate for 1-, 2-, and
3-years of 87 2%, 80.0 2%, 72 3%, andNo-MetS had
91  1%, 86  1%, 83  2%, P  .001 (Fig 1).
Procedural differences. The majority of carotid re-
vascularization procedures were done by CEA (81%) and
the remainder was by CAS (19%). Outcomes were similar
for CEA and CAS for patency, freedom from stroke, sur-
Table II. Complications
CEA
No MetS MetS P
(n%) (n%) value
Systemic
Cardiac 1% 1% .975
Pulmonary 1% 0% .417
Renal 0% 0% .109
Regional
Stroke 1% 4% .027
Transient ischemic attack 1% 2% .269
Bradycardia 1% 0% .279
Hypotension 1% 0% .162
Local
Vasospasm 0% 0% —
Dissection 1% 0% .109
Hematoma 7% 9% .417
Cranial nerve injury 1% 1% .720
Arterio-venous fistula 0% 0% —
Hemorrhage 1% 0% .377
Pseudoaneurysm formation 0% 0% —
Total 12% 17% .109
MetS, Metabolic syndrome; No-MetS, no metabolic syndrome; CEA, caroti
*Significant.vival, and MAE. Patients undergoing CEA had a lower allcause morbidity (15.6% vs 32.2%, P  .001) and lower
30-day mortality (0.7% vs 2.9%, P  .010) than those
undergoing CAS. The combined 30-day stroke and death
rate was lower for CEA patients compared to CAS patients
but statistically insignificant (3.1% vs 5.8%, respectively,
P .077) (Table IV). Additionally, those undergoing CEA
had a greater freedom from MI than those undergoing
Fig 1. Freedom frommajor adverse events (MAE). Two hundred
five (32%) No-MetS and 116 (41%) MetS patients experienced a
MAE (stroke, MI, or death) during follow-up, (P  .05). The
3-year freedom from MAE rates were 42% and 32% for MetS and
No-MetS, respectively. Error bars are omitted for clarity. Standard
error did not exceed 10% at all time intervals that were analyzed.
The number of patients at risk at each time interval is shown below
the Fig.
CAS
MetS
N  288
[n(%)]
No Met-S
N  633
[n(%)] P value
MetS MetS P
%) (n%) value
2% 4% .530 2% 2% .971
0% 3% .125 1% 1% .574
1% 0% .530 1% 1% .557
2% 6% .172 5% 1% .004*
4% 4% .856 4% 2% .560
0% 19% .084 2% 2% .048*
9% 14% .180 1% 2% .025*
4% 8% .367 2% 1% .007*
2% 0% .187 1% 1% .178
8% 4% .290 8% 7% .586
0% 0% — 1% 1% .870
0% 0% — 0% 0% —
0% 0% — 0% 1% .344
1% 1% .914 0% 1% .344
6% 39% .066 23% 14% .001*
rterectomy; CAS, carotid artery stenting.No
(n
1
2
d endaCAS. The 1-, 2-, and 3-year freedom from MI were
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93  2%, 92  2%, and 87  3% for CAS patients (P 
.028). Patients undergoing CAS tended to have a higher
MAE rate. The 3-year freedom fromMAE was 73 4% for
CAS and 81  2% for CEA, P  .070. For freedom from
MI, CAS patients experienced lower rates (93  2%, 92 
2%, 87 3% vs 98 1%, 96.0 0.8%, 94 1% [P .028]
Fig 2. Freedom from stroke. Twenty-seven (4%) No-MetS and
23 (8%) No-MetS patients experienced a stroke during follow-up,
(P .05). The 3-year freedom from stroke rates were 93% and 96%
for MetS and No-MetS, respectively. Error bars are omitted for
clarity. Standard error did not exceed 10% at all time intervals that
were analyzed. The number of patients at risk at each time interval
is shown below the Fig.
Fig 3. Freedom from myocardial infarction (MI). Thirty-four
(5%) No-MetS and 55 (19%) MetS patients experienced an MI
during follow-up, (P  .05). The 3-year freedom from MI rates
were 88% and 96% for MetS and No-MetS, respectively. Error bars
are omitted for clarity. Standard error did not exceed 10% at all
time intervals that were analyzed. The number of patients at risk at
each time interval is shown below the fig.for 1-, 2-, and 3-year rates between CAS and CEA, respec-tively). CEA patients exhibited higher freedom from reste-
nosis rates (91  1%, 87  1%, 84  2% vs 77  5%, 74 
5%, 70 5% [P .001] for 1-, 2-, and 3-year rates between
CEA and CAS, respectively), but equivalent patency rates
(Fig 5).
Hazards analysis. Results of Cox proportional haz-
ards models are listed in Table V. After adjustment for age,
gender, history of MI, congestive heart failure, atrial fibril-
lation, and COPD, patients with MetS had 54% and 361%
greater risk of developing MAE and MI compared with
those without MetS, respectively. In addition, age, history
of AFIB, and history of COPD were significant associated
with risk of developing MAE; age, male, and history of
CHF were significant associated with risk of developing
MI. Among patients with diabetes, patients with MetS had
68% and 410% higher respective risk of developing MAE
and MI compared with those without MetS after adjust-
ment for the same variables listed above, respectively. In
addition, age and history of CHF were significantly associ-
ated with risk of MAE and age, male, and history of CHF
were significantly associated with risk of MI. For patients
without diabetes, MetS was not significantly associated
with MAE, stroke, or MI. No factors were found be signif-
icantly associated with risk of stroke in all cases (in all
patients, patients with diabetes, and patients without dia-
betes).
When considering each component of MetS in the Cox
proportional models, age (hazard ratio [HR] 1.06, 1.04-
1.07, P  .001), diabetes (HR  1.35, 1.04-1.77, P 
.03), elevated blood pressure (systolic blood pressure140
mm Hg or diastolic blood pressure 90 mm Hg) (HR 
9.6, 1.62-56.92, P .01), hypertension treatment (HR
Fig 4. Survival. Four hundred sixty-one (72%) No-MetS and 201
(71%) MetS patients survived during follow-up, (P  NS). the
3-year survival rates were 84% and 87% for MetS and No-MetS,
respectively. Error bars are omitted for clarity. Standard error did
not exceed 10% at all time intervals that were analyzed. The
number of patients at risk at each time interval is shown below the
Fig.0.12, 0.02-0.71, P  .02), history of AFIB (HR  1.62,
d enda
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1.03-2.06, P  .03) were significant predictors of risk of
MAE. Age (HR  1.07, 1.03-1.11, P .001), male (HR
2.23, 1.20-4.13, P  .01), diabetes (HR  2.79, 1.63-
4.78, P  .001), elevated triglycerides (150 mg/dL)
(2.17, 1.22-3.87, P  .01), reduced HDL (40 mg/dL
for men,50 mg/dL for women) (1.77, 1.02-3.07, P
.04), and history of CHF (HR  2.96, 1.41-6.22, P 
.01) were significantly associated with risk of MI. No
factors were found be significantly associated with risk of
stroke.
DISCUSSION
General. In this study, we analyzed the presence of
MetS and its relation to short- and long-term outcomes in
921 patients undergoing carotid revascularization for both
symptomatic and asymptomatic disease. We foundMetS to
be highly prevalent among patients undergoing carotid
revascularization. Our prevalence of MetS in patients un-
Fig 5. Freedom from restenosis. The 3-year freedom from reste-
nosis rates were 84% and 70% for patients undergoing CEA and
CAS, respectively. Error bars are omitted for clarity. Standard error
did not exceed 10% at all time intervals that were analyzed. The
number of patients at risk at each time interval is shown below the
Fig.
Table IV. 30-Day outcomes
CEA
MetS
n (%)
No MetS
n (%)
Mortality 0.5% 0.7%
Stroke 4.8% 1.7%
Myocardial infarction 1.4% 0.6%
Combined stroke & death 5.2% 2.2%
Major adverse event 5.7% 2.8%
Morbidity 16.7% 12.2%
MetS, Metabolic syndrome; No-MetS, no metabolic syndrome; CEA, carotidergoing carotid revascularization of 31% was similar toGorter et al,17 who found MetS present in 39-44% of
patients with cerebral vascular disease. MetS patients had a
twofold increase in their 30-day MAE rate. The MAE rate
difference continued past 30-days and remained statistically
higher at 90 days and during the remainder of clinical
follow-up. The presence of MetS did not predispose pa-
tients to have poorer patency and freedom from restenosis
outcomes. However, those with MetS had statistically sig-
nificant higher stroke,MI, and complication rates. A strong
covariant in this analysis was the diagnosis of diabetes. For
patients without diabetes, MetS was not significantly asso-
ciated with MAE, stroke, or MI.
Metabolic syndrome definition. There are multiple
definitions of MetS.18-22 Our definition is similar to the
National Cholesterol Education Program (NCEP) defini-
tion14 in the scoring system for four of the five criteria. We
substituted abdominal obesity with a BMI 30 kg/m2.
Due to the retrospective design of our study, we could not
determine the abdominal circumference of each individual
patient, as it is not routinely determined. However, we also
analyzed the short- and long-term outcomes using the
World Health Organization (WHO) definition23 of MetS,
which permits substituting an elevated BMI 30 kg/m2
for abdominal obesity. Using theWHOdefinition ofMetS,
our results remained consistent to the results using our
modified NCEP definition. However, total body fatness,
measured by BMI, is insufficiently sensitive as a risk factor,
and fat distribution (upper-body vs low-body type, as re-
flected by waist circumference and waist:hip ratio) appears
to have a more unique prognostic value.24 A recent paper
on cerebrovascular events showed that markers of abdom-
inal adiposity showed a graded and significant association
with risk of stroke/TIA, independent of other vascular risk
factors. Waist circumference and related ratios were better
at predicting cerebrovascular events than BMI. BMI
showed a positive association with cerebrovascular risk
which became nonsignificant after adjustment for physical
inactivity, smoking, hypertension, and diabetes (odds ratio
1.18; 95% CI, 0.77 to 1.79, top tertile vs bottom tertile).25
Diabetes mellitus as a risk factor. Others26,27 have
previously examined DM as a potential risk factor for
morbidity surrounding carotid revascularization. Our find-
ings were consistent, and found DM patients to have equal
CAS
P value
MetS
n (%)
No MetS
n (%) P value
0.689 4.1% 2.1% 0.318
0.025 5.4% 2.2% 0.436
0.228 6.8% 1.0% 0.043
0.031 6.8% 5.2% 0.417
0.053 9.5% 6.2% 0.335
0.109 40.5% 25.8% 0.089
rterectomy; CAS, carotid artery stenting.morbidity with non-DM patients (15.1% vs 17.8%, P 
lation;
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ence existed between diabetics and non-diabetics (3.1% vs
3.0%, P .96). For 30-day MI, again no difference existed
between diabetics and non-diabetics (1.7% vs 1.1%, P 
.46). For all perioperative cardiac complications, the two
groups were similar (2.1% vs 1.6%, P  .62). However,
during long-term follow-up those patients with DM had
statistically lower survival, freedom from MI, and freedom
fromMAE, but equivalent long-term freedom from ipsilat-
eral stroke. While DM increases the perioperative risk of
other vascular procedures, we did not find the presence of
DM to influence perioperative outcomes for carotid revas-
cularization. However, when we excluded patients with a
pre-existing diagnosis of diabetes and looked at the truly
prediabetic patients in the metabolic syndrome group, the
influence of the diagnosis of metabolic syndrome was not
significant. It, therefore, appears the patients with meta-
bolic syndrome who have diabetes as a qualifying criterion
are the higher risk category. This conclusion may be a type
II error and further work on a large population set is likely
necessary to completely answer this question.
Age greater than 80. As shown in the Results section,
a patient’s age greater than 80 years was found as a negative
risk factor for survival, freedom fromMI, and freedom from
MAE. The lower long-term survival rates are not unex-
pected. While this group of patients fared worse in freedom
from MI and MAE, it is important to point out that they
Table V. Hazards ratios (HR) of major adverse event (MA
Variable
MAE
HR (95% CI)
All patients
MetS 1.54 (1.15–2.05)
Age (year) 1.05 (1.04–1.07)
Male vs female 1.28 (0.96–1.70)
History of
MI 1.02 (0.75–1.39)
CHF 1.42 (0.92–2.18)
AFIB 1.61 (1.13–2.30)
COPD 1.44 (1.02–2.04)
Patients with DM
MetS 1.68 (1.07–2.63)
Age (year) 1.05 (1.02–1.08)
Male vs female 1.46 (0.89–2.40)
History of
MI 0.80 (0.49–1.32)
CHF 1.97 (1.04–3.72)
AFIB 1.18 (0.64–2.18)
COPD 1.61 (0.91–2.85)
Patients without DM
MetS 1.02 (0.64–1.62)
Age (year) 1.06 (1.04–1.08)
Male vs female 1.15 (0.80–1.65)
History of
MI 1.23 (0.82–1.83)
CHF 1.10 (0.58–2.09)
AFIB 1.79 (1.13–2.83)
COPD 1.47 (0.93–2.32)
MI, Myocardial infarction; CHF, congestive heart failure; AFIB, atrial fibrildid not have higher rates of MetS, which was also shown tolower these outcomes. Patients over the age of 80 years had
a 23.6% rate of MetS compared to those under 80 years
with a 32.5% rate, P  .02. In the short-term, age did not
appear to influence outcomes. Those greater than 80 years
of age had equivalent 30-day and 90-day MAE rates with
those under the age of 80 years (respectively: 1.7% vs 2.1%,
P  .727; 3.4% vs 2.5%, P  .508). The type of carotid
revascularization did not differ between the two age
groups, 77.6% of those 80 years undergoing CEA and
82.3% of those 80 years undergoing CEA (P  .147).
Examining the subgroup of patients greater than 80
years of age demonstrates multiple differences in outcomes
based upon type of carotid revascularization. Those greater
than 80 years had higher morbidity while undergoing CAS
as opposed to CEA (35.9% vs 13.3%, P  .001, respec-
tively). These CAS patients had greater 30-day stroke (7.7%
vs 3.0%, P  .001), 30-day MI (5.1% vs 1.5%, P  .001),
and death rates (5.1% vs 0.7%). The 30-day MAE and
90-dayMAE rates were also higher for CAS patients greater
than 80 years (10.3% vs 4.4%, P .001; 17.9% vs 6.7%, P
.001) when compared to those patients greater than 80
years and undergoing CEA. While the differences are clear
in outcomes between these two procedures for this age
group, we cannot exclude the possibility of bias towards
procedure selection for this age group in that the greater
“optimized” patients were steered towards CEA and the
nd myocardial infarction (MI)
MI
P value HR (95% CI) P value
 .01 4.61 (2.72–7.81)  .001
 .001 1.07 (1.03–1.10)  .001
.09 2.33 (1.27–4.29)  .01
.88 0.82 (0.47–1.45) .50
.11 2.53 (1.25–5.12) .01
 .01 1.06 (0.52–2.14) .87
.04 1.69 (0.92–3.09) .09
.02 5.10 (2.21–11.76)  .001
 .01 1.11 (1.06–1.67)  .001
.13 4.71 (1.76–12.63)  .01
.38 0.91 (0.45–1.82) .79
.04 4.71 (1.97–11.22)  .001
.59 0.44 (0.17–1.13) .09
.10 2.12 (0.99–4.55) .05
.94 1.91 (0.73–5.03) .19
 .001 1.06 (1.01–1.12) .02
.44 1.19 (0.50–2.80) .69
.31 0.69 (0.23–2.10) .52
.77 0.67 (0.09–5.13) .70
.01 1.24 (0.35–4.36)
.09 1.50 (0.50–4.50) .47
COPD, chronic obstructive pulmonary disease.E) aremainder was offered CAS.
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or difference among outcomes between CEA and CAS are
continually debated. As reported in the Results discussion,
the MetS patients suffered higher morbidity rates and
poorer long-term outcomes, but also underwent CAS at a
higher rate as compared to the No-MetS group, which was
more likely to undergo CEA for revascularization. For the
short-term outcomes the CEA group had lower 30-day
mortality and morbidity. To assure these outcome differ-
ences involved the presence of MetS and not just the
procedure performed, we isolated the procedure groups,
and compared the MetS and No-MetS patients for each
revascularization type. For the CEA patients alone, those
identified with MetS had a higher 30-day stroke rate (4.8%
vs 1.7%, P .025) and a greater combined stroke and death
rate (5.2% vs 2.2%, P  .031). For the CAS patients alone,
those identified asMetS had a greater 30-dayMI rate (6.8%
vs 1.0%, P  .043) (Table IV).
Future directions. Glitazones have been shown to
reduce ischemic damage after middle cerebral artery occlu-
sion in animal models.28-32 If future studies support hyper-
glycemia and metabolic syndrome as a risk factor for peri-
operative events during carotid revascularization, then a
study examining the potential benefit of glitazones during
the perioperative period would be interesting.
Study limitations. This study is retrospective in na-
ture and clinical decision-making was individual not to a
standard protocol. The definitions of metabolic syndrome
are continual changing and we have used a surrogate
marker of body adiposity that is not currently in all defini-
tions of metabolic syndrome. We did not have formal
neurological assessments or biochemical assessments of
myocardial ischemia which have been the norm in clinical
trials and may have led us to under report stroke and MI.
CONCLUSION
MetS is prevalent among patients undergoing carotid
revascularization. MetS patients are at a greater risk for
perioperative morbidity as well as stroke, MI, and major
adverse events during follow-up when compared to pa-
tients without MetS. Long-term stroke prevention is poor
in the presence of MetS. MetS should be considered a
significant risk factor for patients undergoing carotid revas-
cularization. However, for patients without diabetes, MetS
was not significantly associated with MAE, stroke, or MI.
No factors were found to be significantly associated with
risk of stroke in all cases (in all patients, patients with
diabetes, and patients without diabetes).
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Dr Frederick P. Beavers (Washington, DC). I have a couple
of questions, but before I ask them I’d like to preface those
questions by the following comments.
Recently in the lay press, there have been questions as to
whether the medical community as well as the pharmaceutical
industry, is developing new diagnoses. Some of those listed are
prehypertension, erectile dysfunction, and restless leg syndrome.
And one of these may be metabolic syndrome.
My questions to you are the following: reviewing the meta-
bolic syndrome criteria, it appears that 31% of the patients reviewed
had a metabolic syndrome; 38% fell short, only having 2 of the 5
required criteria. Did you do an analysis to see if there was any
difference between the two groups?
The second question is, did you think it wise to include or
group the carotid endarterectomy and the carotid artery angio-
plasty groups into this study given the controversies as to whether
these are equivalent therapies or one has a higher morbidity and
mortality risk?
Dr Protack. In answer to your first question, we did not
analyze our data based on whether a patient had 1, 2, 3, 4, or 5 of
the factors present, and see if the number of factors correlated.
In answer to your second question we chose to look at the
entire population as this was retrospective and we presumed was
the best practice during the period. However, in the paper we did
look at subgroups based on intervention: in those patients who
underwent carotid endarterectomy, there were differences be-
tween patients with and without metabolic syndrome; similarly
there were differences between patients with and without meta-
bolic syndrome that received carotid stents.
Dr Karl Illig (Rochester, NY). Do you think metabolic
syndrome is a real entity or is it just one end of the bell-shapedDr Protack.Metabolic syndrome is considered a real entity by
most in academic health care and public policy has been adapted to
develop intervention strategies to combat the individual elements.
Dr Brajesh Lal (Newark, NJ). I think the true answer is that
metabolic syndrome is just a collection of risks factors that you’ve
decided to give a name – hypertension, diabetes, hyperlipidemia.
What you’ve really done statistically, is eliminate carotid stent-
ing and endarterectomy from the picture. You have identified a
group of patients that were sick and therefore they died or had an
MI. If they were sicker, more would die or have an MI. And if they
were the sickest group, even more would die and have an MI.
So my question to you is, what does carotid endarterectomy
and stenting have to do at all with your results? What you’ve
proven to me is that metabolic syndrome is a risk factor for MI and
death.
Dr Protack. The definitions of metabolic syndrome is not
ours but is that of the major medical professional and health policy
organizations. I agree that metabolic syndrome groups the various
risk factors together but the consensus of opinion is that this leads
to synergy and potentially greater risk than the aggregate of the
individual risk factors. In this study, we saw an increase in stroke
which is one of the principal outcomes measures for carotid inter-
ventions, and so is important for vascular surgeons to know and
understand in the context of carotid disease.
Dr Martin Back (Tampa, Fla). For clarity of discussion,
metabolic syndrome was not a marker for long-term survival or
death. It was a marker for late MI. Periprocedurally there was a
higher rate of stroke in patients with metabolic syndrome. And you
said, to clarify Dr Beavers’ point, that stroke was more common in
patients with metabolic syndrome who underwent carotid stenting
as well as carotid endarterectomy. Is that correct?Dr Protack. Yes, that is correct.
61  3.0% 70  2.1%
JOURNAL OF VASCULAR SURGERY
Volume 49, Number 5 Protack et al 1180.e1Table III online only. Long-term outcomes
Total
n  921
n (%)
Patency
1-year 99  0.3%
2-year 99  0.5%
3-year 99  0.5%
4-year 98  0.6%
5-year 98  0.6%
Freedom from restenosis
1-year 89  1.2%
2-year 85  1.4%
3-year 82  1.6%
4-year 81  1.7%
5-year 78  1.9%
Freedom from stroke
1-year 97  0.6%
2-year 96  0.6%
3-year 95  0.7%
4-year 95  0.7%
5-year 94  0.9%
Freedom from myocardial infarction
1-year 97  0.6%
2-year 95  0.7%
3-year 93  0.9%
4-year 92  1.0%
5-year 90  1.2%
Survival
1-year 94  1.0%
2-year 90  1.0%
3-year 86  1.1%
4-year 80  1.4%
5-year 75  1.7%
Freedom from major adverse event
1-year 90  1.0%
2-year 84  1.2%
3-year 79  1.4%
4-year 73  1.6%
5-year 68  1.8%MetS No Met-S
P value
n  288 n  633
n (%) n (%)
99  0.7% 99  0.5% .074
97  1.1% 99  0.5%
96  1.4% 99  0.5%
96  1.4% 99  0.6%
96  1.4% 99  0.6%
88  2.2% 89  1.4% .390
86  2.4% 85  1.7%
80  3.0% 84  1.8%
79  3.1% 82  2.0%
76  3.7% 80  2.3%
95  1.3% 97  0.7% .027
95  1.3% 97  0.7%
93  1.3% 96  0.7%
92  1.7% 96  0.8%
92  1.8% 95  0.9%
95  1.2% 98  0.6%  .001
92  1.6% 96  0.8%
88  2.0% 96  0.9%
86  2.2% 95  1.0%
80  3.0% 94  1.1%
93  1.5% 94  1.0% .451
88  1.9% 90  1.2%
84  2.2% 87  1.4%
81  2.5% 80  1.8%
74  3.1% 75  2%
87  2.0% 91  1.2%  .001
80  2.4% 86  1.4%
72  2.7% 83  1.5%
67  2.9% 76  1.9%
